- Home
- EFSC vs AKRO Comparison
EFSC vs AKRO Comparison
Compare EFSC & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EFSC
- AKRO
- Stock Information
- Founded
- EFSC 1988
- AKRO 2017
- Country
- EFSC United States
- AKRO United States
- Employees
- EFSC N/A
- AKRO N/A
- Industry
- EFSC Major Banks
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- EFSC Finance
- AKRO Health Care
- Exchange
- EFSC Nasdaq
- AKRO Nasdaq
- Market Cap
- EFSC 2.0B
- AKRO 2.1B
- IPO Year
- EFSC 1999
- AKRO 2019
- Fundamental
- Price
- EFSC $54.02
- AKRO $31.59
- Analyst Decision
- EFSC Strong Buy
- AKRO Strong Buy
- Analyst Count
- EFSC 4
- AKRO 7
- Target Price
- EFSC $51.75
- AKRO $43.20
- AVG Volume (30 Days)
- EFSC 128.3K
- AKRO 441.5K
- Earning Date
- EFSC 10-21-2024
- AKRO 11-11-2024
- Dividend Yield
- EFSC 2.11%
- AKRO N/A
- EPS Growth
- EFSC N/A
- AKRO N/A
- EPS
- EFSC 4.72
- AKRO N/A
- Revenue
- EFSC $591,631,000.00
- AKRO N/A
- Revenue This Year
- EFSC N/A
- AKRO N/A
- Revenue Next Year
- EFSC $1.49
- AKRO N/A
- P/E Ratio
- EFSC $11.27
- AKRO N/A
- Revenue Growth
- EFSC N/A
- AKRO N/A
- 52 Week Low
- EFSC $34.26
- AKRO $11.36
- 52 Week High
- EFSC $54.88
- AKRO $37.00
- Technical
- Relative Strength Index (RSI)
- EFSC 61.25
- AKRO 66.34
- Support Level
- EFSC $51.31
- AKRO $29.34
- Resistance Level
- EFSC $53.55
- AKRO $32.15
- Average True Range (ATR)
- EFSC 1.33
- AKRO 1.26
- MACD
- EFSC 0.18
- AKRO 0.10
- Stochastic Oscillator
- EFSC 100.00
- AKRO 99.74
About EFSC Enterprise Financial Services Corporation
Enterprise Financial Services Corporation is a financial holding company. It offers banking and wealth management services to individuals and business customers located in Arizona, California, Florida, Kansas, Missouri, Nevada, and New Mexico, in addition to loan and deposit production offices throughout the United States. The company offers a broad range of business and personal banking services including wealth management services. Lending services include commercial and industrial, commercial real estate, real estate construction and development, residential real estate, and consumer loans.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.